Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643399 | 1.00 | HTR2C (0.52) | HTR2CSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL3029470 | 0.92 | HTR2C (0.53) | HTR2CSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL31700094 | 0.86 | HTR2C (0.50) | HTR2CPARP1 | |
| SCHEMBL30523584 | 0.86 | HTR2C (0.55) | HTR2CSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL19271743 | 0.86 | HTR2C (0.55) | HTR2CSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL21872248 | 0.86 | HTR2C (0.55) | HTR2CSMN1; SMN2NPC1RAB9APSEN1 | |
| SCHEMBL2391599 | 0.84 | AOC3 (0.52) | HTR2CSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL812802 | 0.84 | SMN1; SMN2 (0.55) | HTR2CSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL2390727 | 0.84 | PSEN1 (0.51) | HTR2CSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL3823845 | 0.83 | NPC1 (0.50) | HTR2CSMN1; SMN2CYP2C19NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-115551867-B | Fused tricyclic compounds, pharmaceutical compositions and uses thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4159739-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| CN-115551867-A | Fused tricyclic compound, pharmaceutical composition and application thereof | 劲方医药科技(上海)有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | HTR2C 4637/4885SMN1; SMN2 2665/4885CYP2C19 4752/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | HTR2C 2821/4885SMN1; SMN2 3268/4885CYP2C19 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.